Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
1.
EuroIntervention ; 9(2): 204-11, 2013 Jun 22.
Article in English | MEDLINE | ID: mdl-23454910

ABSTRACT

AIMS: Surgery after drug-eluting stent (DES) implantation may be associated with increased risk for perioperative stent thrombosis (ST). METHODS AND RESULTS: We evaluated the outcomes of 67 patients who underwent non-cardiac (n=51) or cardiac (n=16) surgery after DES implantation at our institution between 2008 and 2010 and who underwent preoperative "bridging" with a glycoprotein IIb/IIIa inhibitor. Surgery occurred after a mean time of 13.9 ± 1.7 and 8.7 ± 2 months post stenting for non-cardiac (NCS) and cardiac surgery, respectively. Glycoprotein IIb/IIIa inhibitors were administered preoperatively for a mean of 7.1 ± 0.4 and 7.8 ± 0.7 days, respectively, then discontinued four to six hours before surgery. Most patients received aspirin through the perioperative period (33 NCS patients and 15 cardiac surgery patients). Clopidogrel was restarted as early as possible in the postoperative period. In the non-cardiac surgery group, two patients (3.9%, 95% confidence intervals 0.5% to 13.5%) suffered acute ST in the immediate postoperative period and four patients suffered major bleeding by the Global Utilisation of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) criteria. One cardiac surgery patient had probable ST one hour postoperatively. CONCLUSIONS: In spite of preoperative "bridging" with a glycoprotein IIb/IIIa inhibitor, postoperative stent thrombosis can still occur in patients with prior DES undergoing surgery requiring antiplatelet medication interruption.


Subject(s)
Cardiac Surgical Procedures , Coronary Thrombosis/prevention & control , Drug-Eluting Stents , Percutaneous Coronary Intervention/instrumentation , Platelet Aggregation Inhibitors/administration & dosage , Platelet Glycoprotein GPIIb-IIIa Complex/antagonists & inhibitors , Pyridines/administration & dosage , Aged , Cardiac Surgical Procedures/adverse effects , Coronary Thrombosis/blood , Coronary Thrombosis/etiology , Drug Administration Schedule , Female , Humans , Male , Middle Aged , Percutaneous Coronary Intervention/adverse effects , Perioperative Care , Platelet Aggregation Inhibitors/adverse effects , Prosthesis Design , Pyridines/adverse effects , Retrospective Studies , Texas , Time Factors , Treatment Outcome
2.
J Clin Anesth ; 21(3): 183-9, 2009 May.
Article in English | MEDLINE | ID: mdl-19464611

ABSTRACT

STUDY OBJECTIVE: To define the various factors that influence the rate of effective preoxygenation. DESIGN: Prospective, randomized study. SETTING: Procedure room in a teaching hospital. SUBJECTS: 14 ASA physical status I volunteers who performed 4 sessions of breathing in random order. Of these volunteers, 7 performed two extra sessions using vital capacity breathing, which were also completed in random order. INTERVENTIONS: Using the circle system, volunteers breathed with a mouthpiece and nose-clip until expired nitrogen reached 5%, using either a fresh gas flow of 5 L/min or 10 L/min or a system flushed with O(2). MEASUREMENTS: End-expired levels of O(2), nitrogen, and CO(2) were recorded. MAIN RESULTS: Minute ventilation, functional residual capacity, and age were significant factors for rate of denitrogenation. However, height and weight were not significant factors in predicting time to denitrogenation. At low flow rates, flushing with O(2) significantly decreased the time of denitrogenation. There appeared to be little clinical benefit of flushing with O(2) when a 10 L/min O(2) flow was used. CONCLUSIONS: A high gas flow rate appears critical to achieving rapid preoxygenation.


Subject(s)
Carbon Dioxide/metabolism , Nitrogen/metabolism , Oxygen/metabolism , Adult , Female , Hospitals, Teaching , Humans , Male , Middle Aged , Oxygen/administration & dosage , Prospective Studies , Respiratory Physiological Phenomena , Vital Capacity/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...